



NCCP NATIONAL EXECUTIVE TEAM MEETING

Date: Monday 7th April 2025 @ 10.30am, MS Teams

Present: R. Ó Laoide (Chair), F. Bonas, C. Faul, T. Hanan, P. Heckmann, A. Hill, T. Holohan, T.

McCarthy, D. O'Shea

Apologies: M. Keane, L. Smyth

Invited: R. Conway, T. Flattery, J. Gleeson and C. Mellett.

For Item A1: D. Galvin, E. O'Toole

For Item A2: L. Ryan

A. PRES	ENTATIONS	
A1	Overview of two National Clinical Guidelines: (Dr. David Galvin and Dr. E. O'Toole, Co-Chairs Prostate Cancer National Guideline Development Group) 1. HSE National Clinical Guideline: National Clinical Guideline: Active surveillance for patients with prostate cancer 2. HSE National Clinical Guideline: The Use of Focal Therapy in Patients with Prostate Cancer • The Executive approved the two guidelines and acknowledged the work of Dr. D. Galvin, Dr. E. O'Toole and the Guideline Development Group and the	
	NCCP Evidence & Quality team in the development of the guidelines.	
A2	Strategic Planning for Cancer Control (R. Ó Laoide, T. Holohan)	
	 The NCCP approach to a number of inter-related strategic projects was discussed. Action: Further discussion to take place with NCCP National Clinical Advisors for Surgical Oncology, Radiation Oncology, Medical Oncology and Haemato-Oncology. 	
B. MIN	UTES & MATTERS ARISING	
B1	Minutes of the previous meeting	
D1	The minutes of March 10 th meeting were agreed subject to a minor	
	amendment.	
B2	Matters Arising	
	None	
C. DIREC	TOR'S ITEMS	
C1	Regions Work is continuing in relation to the NCCP's engagement with the health	
	 regions. The REOs have reviewed the draft MOU between the NCCP and the regions and detailed feedback is awaited. A meeting with the REO group is being scheduled for the end of Q2. 	

HSE Centre and Board

 The NCCP is awaiting further information from the CCO's Office on requirements for reports to the HSE Board on clinical services.

New Cancer Strategy

• The importance of developing the next Cancer Strategy within the usual 10 year cycle has been discussed with the Department of Health.

NCCP Clinical leads

• Recruitment for a urological cancer lead is progressing.

Stakeholder events

Recent event:

• 4th April – NCCP Lung Cancer Audit, Quality and Risk Forum

Upcoming launch:

• 16th May – Launch of four national clinical guidelines

D. STANDING ITEMS

D1 EU Cancer Projects

CCI4EU

- CCI4EU is the EU project focused on developing cancer care infrastructure.
- The second round of Deep Dive meetings took place on April 1st in Galway and April 2nd in Dublin.
- There was excellent attendance on both days and the EU Deep Dive team were pleased with the engagement and progress.
- The third and final deep dive meetings have been scheduled for September 1st and 2nd.
- EUNetCCC project is now live. Ireland is participating in a pilot project related to the CraNE output on CCC standards.

D2 National Service Plan 2025

- Primary notifications have been issued by the HSE.
- Work is ongoing to finalise communications from the CEO regarding commissioning new service developments for cancer services.
- Concern raised regarding the timelines, given the requirement to recruit and onboard staff by the end of 2025.

E1 Cancer Intelligence (T. Holohan/R. Conway)

Update covered under agenda item.

E2 Surgical Oncology Programme (F. Bonas/A. Hill)

• Gynae-oncology – recent meeting with clinical leads in Limerick to progress the implementation of NCIS.

E3 Surgical Centralisation (A. Hill/T. Holohan/F. Bonas)

- Implementation of centralisation plans is ongoing.
- RPLND process is ongoing in relation to the designation of a national centre for RPLND surgery.
- Pelvic Exenteration update awaited on new UK standards and guidelines

	which are expected to be published in May.	
E4	Medical Oncology/ Haemato-oncology/Molecular (P. Heckmann/D. O'Shea)	
E4	 Systemic Therapy Programme (STP)/Cancer Drug Management Programme (CDMP)/Molecular Sláintecare Integration Fund (SIF): STP are undertaking some work on a potential proposal for compounding robots for 3 cancer centres in the Round 4 calls for this fund. Drug funding: Recent meeting with the HSE CCO to discuss drug funding pathways. Further information to be provided on the proposal for paediatrics and post pubescent children. Two new drugs approved for metastatic colorectal cancer (mCRC) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). NCCP Guidance Documents on the Safe Use of Intrathecal Chemotherapy and Neurotoxic Drugs were revised and updated by the NCCP Intrathecal Chemotherapy Working Group in March. 	
	 Molecular Genomic Test Directory for lung, melanoma and prostate cancer agreed and update to Urothelial Test directory (testing for new SACT indications) by NCCP Molecular Diagnostics Advisory Group. These will be published shortly on the NCCP website. First meeting of the Radioligand Therapy Advisory Group has taken place. 	
E5	National Cancer Information System (NCIS) – P. Heckmann	
	 Roll-out continuing: 21 of 26 hospitals live - including 7 of the 9 cancer centres. Cork University Hospital went live with first Tumour Conference (Neurology) on March 13th. Plan to follow quickly with SACT ordering and preparation functionality. Wexford General Hospital and Tallaght University Hospital are progressing with implementation projects. University Hospital Waterford go-live date has been postponed until Q2 2025 due to resource challenges. PID for Mater Misericordiae University Hospital is under review. Portiuncula Hospital is experiencing a challenge in resourcing the project. 	
E6	Radiation Oncology (F. Bonas/C. Faul)	
	 KPI performance has improved. Artificial Intelligence (AI) group – the group has completed a national survey of all centres. Further area of focus will be on the evaluation of AI implementation processes. National Programme for Radiation Oncology (NPRO) – Beaumont Phase II development is due to commence in Q1 2027. Plan to further roll out of SABR programme in Cork and Galway. Upcoming meeting of the North/South shared Island group. UPMC contract – process is nearing completion. 	
E7	Cancer Networks (F. Bonas/J. Gleeson)	
	 Meetings will continue pending the formalisation of the proposed MOU with Health Regions. 	
E8	Community Oncology (T. McCarthy)	

DATE OF	NEXT MEETING	
G	AOB	
	 National Cancer Care Experience Survey (CCES) - The first draft of the questionnaire has been shared with NCCP staff for feedback. The Executive noted new and revised KPIs will need to be aligned with accreditation and EU standards 	
F	FOR INFORMATION	
	 AHOS - The service will mark five years in operation at a conference in September. Survivorship – radiation oncology continuing to progress readiness for self-stratified management follow up. St. James' Hospital will be the first site. Education – The NCCP nursing team have been shortlisted as a finalist at the Irish Healthcare awards following submission of the NCCP National SACT Competency Programme for Nurses Working in Cancer Care. 	
E9	Cancer Nursing (T. Hanan)	
	 A systematic review of the effectiveness of cancer awareness campaigns is underway. The SunSmart campaign is now live and will run from April to September. The 2024 Evaluation of the Introduction of the Senior Health Promotion and Improvement Officers-Cancer Prevention Roles and Practitioner Network was noted by the Executive. 	